Use and misuse of buprenorphine in the management of opioid addiction

Journal of Opioid Management

Volumn 3, Issue 6, 2007, Pages 302-308

  Cicero, Theodore J ^a   Surratt, Hilary L ^b   Inciardi, James ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF DELAWARE   (United States)

Author keywords

Buprenorphine abuse; Buprenorphine misuse; Opioid abuse; Prescription opioid abuse; Treatment

Indexed keywords

BUPRENORPHINE; FENTANYL; HYDROCODONE; HYDROMORPHONE; METHADONE; MORPHINE; OXYCODONE; TRAMADOL;

ADULT; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG ABUSE; DRUG DETOXIFICATION; DRUG MISUSE; DRUG USE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; OPIATE ADDICTION; PRESCRIPTION; QUESTIONNAIRE; STATISTICAL ANALYSIS;

EID: 38649133872     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2007.0018     Document Type: Article

References (23)

1. Fudala PJ, Bridge TP, Herbert S, et al.: Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003; 349(10): 949-958.
2. Fiellin DA, O'Connor PG.: New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med. 2002; 137(8): 688-692.
3. Fiellin DA, Pantalon MV, Chawarski MC, et al.: Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006; 355(4): 365-374.
4. Comer SD, Collins ED, Fischman MW.: Intravenous buprenorphine self-administration by detoxified heroin abusers. J Pharmacol Exp Ther. 2002; 301(1): 266-276.
5. Pickworth WB, Johnson RE, Holicky BA, et al.: Subjective and physiologic effects of intravenous buprenorphine in humans. Clin Pharmacol Ther. 1993; 53(5): 570-576.
6. Mendelson J, Jones RT.: Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: Why the 4:1 ratio for treatment? Drug Alcohol Depend. 2003; 70(2S): S29-S37.
7. Fudala PJ, Yu E, Macfadden W, Boardman C, Chiang CN.: Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend 1998; 50(1): 1-8.
8. Mendelson J, Jones RT, Welm S, et al.: Buprenorphine and naloxone combinations: The effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology (Berl). 1999; 141(1): 37-46.
9. Drug Addiction Treatment Act of 2000.: Public Law No. 106-310, Title XXXV-Waiver authority for physicians who dispense or prescribe certain narcotic drugs for maintenance treatment or detoxification treatment. Available at http://www.buprenorphine.samhsa.gov/fulllaw.html. Accessed July 22, 2001.
10. Cicero TJ, Inciardi JA.: Potential for abuse of buprenorphine in office-based treatment of opioid dependence. N Engl J Med. 2005; 353(17): 1863-1865.
11. Cicero TJ, Surratt H, Inciardi JA, Munoz A.: Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States. Pharmacoepidemiol Drug Saf 2007; 16(8): 827-840.
12. Treatment Episode Data Set (TEDS): 1994-2004 Drug and Alcohol Services Information System Series S-33, Department of Health and Human Services Publication No. (SMA) 06-4180; Published 9/2006. 2006 [cited 2006 October 3]; Available at http://wwwdasis.samhsa.gov/teds04/ TEDSAd2k4TOC.htm.
13. Cicero TJ, Lynskey MT, Todorov A, et al.: Comorbid psychopathology and pain in males and females in treatment for opioid analgesic abuse. Pain. In review.
14. American Psychiatric Association.: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
15. Cicero TJ, Adams EH, Geller A, et al.: A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend. 1999; 57(1): 7-22.
16. Cicero TJ, Inciardi JA, Adams EH, et al.: Rates of abuse of tramadol remain unchanged with the introduction of new branded and generic products: Results of an abuse monitoring system, 1994-2004. Pharmacoepidemiol Drug Saf. 2005; 14(12): 851-859.
17. Carrieri MP, Amass L, Lucas GM, et al.: Buprenorphine use: The international experience. Clin Infect Dis. 2006; 43 (Suppl 4): S197-S215.
18. Inciardi JA, Cicero TJ, Munoz A, et al.: The diversion of ultram, ultracet, and generic tramadol HCL. J Addict Dis. 2006; 25(2): 53-58.
19. Cicero TJ, Inciardi JA, Munoz A.: Trends in abuse of oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain. 2005; 6(10): 662-672.
20. Fendrich M, Yun Soo Kim J.: Multiwave analysis of retest artifact in the National Longitudinal Survey of Youth drug use. Drug Alcohol Depend. 2001; 62(3): 239-253.
21. Senay EC.: Clinical experience with T's and B's. Drug Alcohol Depend. 1985; 14: 305-311.
22. Aquilino W.: Interview mode effects in surveys of drug and alcohol use: A field experiment. Public Opin Q. 1994; 58: 210-240.
23. Aquilino WW, Wright DL.: Substance use estimates from rdd and area probability samples: Impact of differential screening methods and unit non-response. Public Opin Q. 1996; 60: 563-573.